Clinical Investigation
Tumor Response and Survival Predicted by Post-Therapy FDG-PET/CT in Anal Cancer

https://doi.org/10.1016/j.ijrobp.2007.09.005Get rights and content

Purpose

To evaluate the response to therapy for anal carcinoma using post-therapy imaging with positron emission tomography (PET)/computed tomography and F-18 fluorodeoxyglucose (FDG) and to compare the metabolic response with patient outcome.

Patients and Methods

This was a prospective cohort study of 53 consecutive patients with anal cancer. All patients underwent pre- and post-treatment whole-body FDG-PET/computed tomography. Patients had been treated with external beam radiotherapy and concurrent chemotherapy. Whole-body FDG-PET was performed 0.9–5.4 months (mean, 2.1) after therapy completion.

Results

The post-therapy PET scan did not show any abnormal FDG uptake (complete metabolic response) in 44 patients. Persistent abnormal FDG uptake (partial metabolic response) was found in the anal tumor in 9 patients. The 2-year cause-specific survival rate was 94% for patients with a complete vs. 39% for patients with a partial metabolic response in the anal tumor (p = 0.0008). The 2-year progression-free survival rate was 95% for patients with a complete vs. 22% for patients with a partial metabolic response in the anal tumor (p < 0.0001). A Cox proportional hazards model of survival outcome indicated that a complete metabolic response was the most significant predictor of progression-free survival in our patient population (p = 0.0003).

Conclusions

A partial metabolic response in the anal tumor as determined by post-therapy FDG-PET is predictive of significantly decreased progression-free and cause-specific survival after chemoradiotherapy for anal cancer.

Anal cancer
Chemoradiotherapy
FDG-PET/CT
Response

Cited by (0)

Presented at the American Radium Society 89th Annual Meeting, May 5–9, 2007, Amsterdam, The Netherlands.

Conflict of interest: none.

View Abstract